GlassScriptPhysician profile
David P Cohen
NPI 1972504611
$3,952.98
in general payments reported to CMS, 2019-2025
16 companies · $898 in 2025
The $898 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2022: $327 · 2023: $1,439 · 2024: $1,177 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,046.80 | 2022-2025 | Skyrizi, Rinvoq, Linzess |
| Gilead Sciences, INC. | $606.43 | 2022-2025 | Epclusa |
| Janssen Biotech, INC. | $368.19 | 2023-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $185.79 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.08 | 2023-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $145.24 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $126.51 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $59.25 | 2024 | |
| Celgene Corporation | $51.91 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $49.47 | 2024-2025 | Vegzelma, Zymfentra |
| Fujifilm Healthcare Americas Corporation | $44.24 | 2023-2024 | Fujifilm |
| Pfizer INC. | $29.83 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $27.03 | 2025 | Iqirvo |
| Exact Sciences Corporation | $24.32 | 2024 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $18.23 | 2023 | Sutab, Suflave |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $15.66 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.